Innate Pharma S.A. EBITDA | IPHA

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.^[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA Innate Pharma S.A.

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-54 M	-51.6 M	-12.7 M	-57.4 M	-47.8 M	1.08 M	1.58 M	5.15 M	-40 M	7.76 M	-10.6 M	-17.6 M	-1.89 M	-2.53 M	-6.65 M

All numbers in EUR currency

Indicator range from annual reports

Maximum	Minimum	Average
7.76 M	-57.4 M	-19.1 M

Quarterly EBITDA Innate Pharma S.A.

2025-Q4	2025-Q2	2024-Q4	2024-Q2	2023-Q4	2023-Q2	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-54 M	-25.4 M	-51.6 M	-26.3 M	-12.7 M	-398 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in EUR currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
-398 K	-54 M	-28.4 M

References

Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Biotechnology industry

Issuer	EBITDA	Price	% 24h	Market Cap	Country
Legend Biotech Corporation LEGN	-136 M	$ 20.39	5.79 %	$ 7.52 B	USA
Ligand Pharmaceuticals Incorporated LGND	74.8 M	$ 308.16	1.53 %	$ 5.96 B	USA
BridgeBio Pharma BBIO	-518 M	$ 68.11	-0.65 %	$ 13 B	USA
Annovis Bio ANVS	-29.7 M	$ 0.95	-4.92 %	$ 19.5 M	USA
Liquidia Corporation LQDA	-49.8 M	$ 43.75	2.58 %	$ 3.77 B	USA
Tyme Technologies TYME	-25.5 M	-	8.07 %	$ 54 M	USA
Lexicon Pharmaceuticals LXRX	-48.3 M	$ 1.46	2.81 %	$ 530 M	USA
Mustang Bio MBIO	-2.4 M	$ 0.36	-1.89 %	$ 1.77 M	USA
BioCryst Pharmaceuticals BCRX	342 M	$ 7.88	3.01 %	$ 1.65 B	USA
Madrigal Pharmaceuticals MDGL	-299 M	$ 437.59	0.77 %	$ 9.82 B	USA
Cyclerion Therapeutics CYCN	-3.21 M	$ 34.99	3.77 %	$ 147 M	USA
Black Diamond Therapeutics BDTX	12.8 M	$ 1.69	-10.37 %	$ 96.1 M	USA
Mirum Pharmaceuticals MIRM	2.11 M	$ 83.44	3.79 %	$ 4.19 B	USA
Aptevo Therapeutics APVO	-26.1 M	$ 1.49	-7.45 %	$ 470 K	USA
MannKind Corporation MNKD	51.1 M	$ 3.23	1.25 %	$ 987 M	USA
Monopar Therapeutics MNPR	-16.7 M	$ 70.52	-0.18 %	$ 523 M	USA
Marker Therapeutics MRKR	-12.9 M	$ 0.9	-6.16 %	$ 13.8 M	USA
Maravai LifeSciences Holdings MRVI	-192 M	$ 7.5	3.69 %	$ 1.08 B	USA
Matinas BioPharma Holdings MTNB	-6.93 M	$ 1.66	-2.92 %	$ 9.09 M	USA
Neurocrine Biosciences NBIX	645 M	$ 145.91	2.25 %	$ 14.5 B	USA
Orgenesis ORGS	-37.7 M	-	-33.86 %	$ 61.2 M	USA
Biogen BIIB	780 M	$ 252.25	0.62 %	$ 37 B	USA
Minerva Neurosciences NERV	-15.1 M	$ 2.2	-4.35 %	$ 18.6 M	USA
Nektar Therapeutics NKTR	-139 M	$ 37.17	-0.12 %	$ 627 M	USA
Nkarta NKTX	-113 M	$ 1.87	4.47 %	$ 138 M	USA
NanoViricides NNVC	-7.79 M	$ 1.37	-2.14 %	$ 27.7 M	USA
Codiak BioSciences CDAK	-64.2 M	-	-55.98 %	$ 2.15 M	USA
Nurix Therapeutics NRIX	-277 M	$ 25.55	0.83 %	$ 2.21 B	USA
Kodiak Sciences KOD	-216 M	$ 89.5	2.13 %	$ 4.76 B	USA
Intellia Therapeutics NTLA	-431 M	$ 11.26	0.4 %	$ 1.22 B	USA
Novavax NVAX	481 M	$ 9.4	-3.14 %	$ 1.52 B	USA
BioLineRx Ltd. BLRX	-10.3 M	$ 2.01	-1.47 %	$ 4.96 B	Israel
Bristol-Myers Squibb Company BMY	4.01 B	$ 61.57	0.15 %	$ 125 B	USA
Novartis AG NVS	17.6 B	$ 153.93	1.86 %	$ 298 B	Schweiz
NextCure NXTC	-55.4 M	$ 5.22	4.72 %	$ 14.8 M	USA
Ocugen OCGN	-60.5 M	$ 0.71	-4.64 %	$ 222 M	USA
Ocular Therapeutix OCUL	-266 M	$ 6.49	-0.23 %	$ 1.22 B	USA
Oragenics OGEN	-9.36 M	$ 0.4	-3.86 %	$ 863 K	USA
Checkpoint Therapeutics CKPT	-56.2 M	-	-	$ 169 M	USA
Omeros Corporation OMER	-122 M	$ 16.27	-1.81 %	$ 1.03 B	USA
Oncolytics Biotech ONCY	-35 M	$ 0.47	-5.91 %	$ 45.1 M	Canada
ORIC Pharmaceuticals ORIC	-142 M	$ 8.99	-31.74 %	$ 789 M	USA
Oramed Pharmaceuticals ORMP	-15 M	$ 4.08	-1.21 %	$ 169 M	Israel
Outlook Therapeutics OTLK	-66.9 M	$ 0.51	-1.71 %	$ 17.7 M	USA
Ovid Therapeutics OVID	-42.2 M	$ 2.15	-0.23 %	$ 280 M	USA
Sage Therapeutics SAGE	-431 M	-	-	$ 527 M	USA
Taro Pharmaceutical Industries Ltd. TARO	49.8 M	-	-	$ 1.62 B	Israel
Nuvation Bio NUVB	-211 M	$ 4.5	-1.53 %	$ 1.54 B	USA
Puma Biotechnology PBYI	48.2 M	$ 10.85	-1.54 %	$ 543 M	USA
Processa Pharmaceuticals PCSA	-14 M	$ 1.76	-2.76 %	$ 2.3 M	USA